NASDAQ:AVR Anteris Technologies Global Q1 2026 Earnings Results & Report $6.30 -0.15 (-2.31%) As of 11:48 AM Eastern This is a fair market value price provided by Massive. Learn more. Anteris Technologies Global missed analyst expectations on both earnings and revenue in its Q1 2026 results, released May 12, 2026. The company reported EPS of -$0.28 versus the -$0.2708 consensus estimate, while revenue of $0.49 million fell short of the $0.77 million estimate by $0.27 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 12, 2026TimeBefore Market OpensConference Call DateMay 11, 2026Conference Call8:00 PM ET Anteris Technologies Global EPS ResultsActual EPS-$0.28Consensus EPS -$0.2708Beat/MissMissed by -$0.0092One Year Ago EPS-$0.61EPS Beat Rate0 of last 4 quartersAnteris Technologies Global Revenue ResultsActual Revenue$0.49 millionExpected Revenue$0.77 millionBeat/MissMissed by -$273.00 thousandYoY Revenue GrowthN/AUpcoming EarningsAnteris Technologies Global's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 17, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Anteris Technologies Global Q1 2026 Earnings FAQ Did Anteris Technologies Global beat earnings estimates for Q1 2026? Anteris Technologies Global (NASDAQ:AVR) reported earnings of -$0.28 per share for Q1 2026, missing the consensus estimate of -$0.2708. The report was announced on Tuesday, May 12, 2026. What was Anteris Technologies Global's revenue for Q1 2026? Anteris Technologies Global reported revenue of $0.49 million for Q1 2026, against a consensus estimate of $0.77 million. When is Anteris Technologies Global's next earnings date? Anteris Technologies Global's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Anteris Technologies Global on the company's earnings history page. Anteris Technologies Global Earnings HeadlinesAnteris Technologies Global Corp. (NASDAQ:AVR) Stock Has Average Target Price of $14.00October 12 at 4:15 AM | americanbankingnews.comAvita Medical (NASDAQ:RCEL) and Anteris Technologies Global (NASDAQ:AVR) Head-To-Head ComparisonOctober 11 at 2:15 AM | americanbankingnews.comMy next big call (under $1)The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a contest offering its biggest holders a seat at dinner with the President. It's also about 97% below its peak. Because a memecoin doesn't benefit from good policy. It benefits from attention. The real winners of a pro-crypto Washington are the projects with actual businesses underneath them. Ones that get more valuable as rules get clearer, institutions get comfortable, and more money flows into the market.October 14 at 1:00 AM | Crypto 101 Media (Ad)Anteris Technologies Global (NASDAQ:AVR) Stock: Insider L1 Capital Pty Ltd Buys 272,695 SharesOctober 10, 2026 | americanbankingnews.comAnteris (NASDAQ: AVR) investor L1 Capital adds shares to its stakeOctober 9, 2026 | americanbankingnews.comAnteris Technologies Expands Unquoted Equity Under Employee Incentive PlanOctober 8, 2026 | tipranks.comSee More Anteris Technologies Global Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Anteris Technologies Global? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anteris Technologies Global and other key companies, straight to your email. Email Address About Anteris Technologies GlobalAnteris Technologies Global (NASDAQ:AVR) is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow. Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution. The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States. Anteris Technologies Global is led by Chief Executive Officer Wayne Patmore and trades on the Nasdaq under the symbol AVR.View Anteris Technologies Global ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
